Clinical trials have been initiated to investigate the effects of combining Azacitidine (Aza), an anti-metabolite chemotherapy drug, with CD47/SIRPα inhibition, such as the anti-CD47 monoclonal antibody (mAb) Magrolimab, in patients with hematologic malignancies. The gene discussed is SIRPA; the disease is hematologic disorder.